Martin Reck, MD, PhD, from the Lung Clinic Grosshansdorf, Grosshansdorf, Germany talks to us about three key topics he presented at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain. The abound2L+ study (NCT02250326) was a Phase II trial which assessed the safety and efficacy of the combination of nab-paclitaxel and either CC-486 or durvalumab in the treatment of advanced non-small cell lung cancer. KEYNOTE-021G (NCT02039674), a Phase II trial, examined the efficacy of pembrolizumab with platinum-based chemotherapy. Finally, the CheckMate153 study (NCT02066636) was a Phase III trial which determined the safety of nivolumab in the treatment of patients with advanced or metastatic non-small cell lung cancer. Prof. Reck discusses the results and their impact in the field.